Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial

Background The efficacy of interleukin-17 inhibitors may be impacted by baseline psoriasis features.Objective This post hoc analysis aimed to explore the efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis stratified by diverse disease features.Methods This post hoc analysis...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jingjing Liu, Junyi Shao, Liyue Hou, Enci Mei, Lili He, Jingying Wang, Anqi Chen, Yi Zhang, Zhiming Li
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2026-12-01
Edice:	Journal of Dermatological Treatment
Témata:	Psoriasis vunakizumab efficacy disease duration disease severity
On-line přístup:	https://www.tandfonline.com/doi/10.1080/09546634.2026.2641340
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!